Harmony Biosciences Holdings

Aging Populations And WAKIX Trials Will Expand Rare Disease Treatment

AnalystHighTarget

Not Invested

Consensus Narrative from 11 Analysts

Published

05 May 25

Updated

15 Aug 25

AnalystHighTarget's Fair Value

US$70.00

47.3% undervalued

15 Aug

US$36.87

5.5%

7.8%

Author's Valuation

US$70.0

47.3% undervalued

AnalystHighTarget Fair Value

Narrative

Updates1

Shared on07 May 25

AnalystHighTarget Fair Value

US$70.0

47.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

15.41%

Pharma revenue growth rate

1.05%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$421.30m

Earnings '28

11.93x

PE Ratio '28

US$5.03b

Market Cap '28

US$5.03b

Market Cap '28

59.68m

No. shares '28

US$84.25

Share Price '28

US$84.25 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$69.20

Fair Value '25